Amgen said on 6 January 2026 that it had acquired Dark Blue Therapeutics, a privately held UK biotech developing small-molecule targeted protein degraders for cancer, in a transaction valued at up to $840m.
Why Amgen Inc. is buying Dark Blue Therapeutics
Amgen said the acquisition complements its research in targeted protein degradation and leukaemia. Dark Blue's lead molecule targets and degrades MLLT1 and MLLT3, proteins that drive specific forms of acute myeloid leukaemia, and preclinical data support use both alone and in combination.
“Acute myeloid leukemia remains one of the most difficult cancers to treat.”
Deal terms and financing
Amgen described the deal as valued at up to $840m and did not break down upfront and contingent payments.
Market context
Amgen plans to integrate Dark Blue into its existing research organisation to strengthen early-stage oncology discovery, according to Indian Pharma Post.
